Entries |
Document | Title | Date |
20080207742 | Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury - The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat head trauma. Specifically, the present invention provides methods of treating head trauma comprising the steps of identifying a subject having suffered a head trauma and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C(PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of head trauma. | 08-28-2008 |
20080214656 | Compounds With Diphenoyl-Structure For the Treatment of Immune Diseases - A composition comprising compounds with a diphenoyl (DP 5 structure for preventing or treating an immune disease and a prophylactic or therapeutic method for the immune disease based on the application of the compounds are provided. The compounds with the DP structure increase the number and activity of regulatory T cells involved in regulating an accelerated immune system. Also, the compounds can be an effective prophylactic or therapeutic agent for various immune diseases including transplantation rejection, graft-versus-host diseases, autoimmune diseases, and hypersensitive inflammatory diseases. | 09-04-2008 |
20080214657 | TOPICAL AVERMECTIN FORMULATIONS AND METHODS FOR ELIMINATION AND PROPHYLAXIS OF SUSCEPTIBLE AND TREATMENT-RESISTANT STRAINS OF HEAD LICE - An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus | 09-04-2008 |
20080227851 | LAULIMALIDE AND LAULIMALIDE ANALOGS - Novel laulimalide analogs, methods for the treatment of proliferative disease and processes for the synthesis of laulimalide and novel laulimalide analogs are described. | 09-18-2008 |
20080249161 | Dermo-Cosmetic Composition For Pets - The invention relates to a dermo-cosmetic composition for pets. This composition includes a diffusion solvent vehicle that enables, by a simple application to one or more points of the cutaneous surface, a diffusion over the entirety thereof and at the level of the sebaceous glands. The active ingredients, primarily include a complex of essential oils and poly-unsaturated fatty acids, stored in the sebaceous glands, can be salted out progressively with the sebum product to the surface of the skin. | 10-09-2008 |
20080249162 | PALMEROLIDES: METHODS OF PREPARATION AND DERIVATIVES THEREOF - Organic compounds having Formulas I and II are provided where the variables have the values described herein. | 10-09-2008 |
20080255223 | Treatment and Prevention of Benign Pigmented Moles (Naevi) Using Artemisinine and the Derivatives Thereof - A method of treating a benign pigmented mole or a dermatomycosis. The method comprises locally applying to a subject in need thereof artemisinine and/or one or more structurally related compounds. Also disclosed is a plaster which comprises a topical formulation comprising artemisinine and/or one or more structurally related compounds. | 10-16-2008 |
20080275106 | Anticancer and Antiprotozoal Dihydroartemisinene and Dihydroartemisitene Dimers with Desirable Chemical Functionalities - This invention comprises compositions containing dihydroartemisinin- and dihydroartemisitene-dimers with activity as anticancer or anticancer metastasis agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer or prevention of cancer metastasis, and protozoal infections, including malaria, or leishmaniasis. The compounds of this invention represent a potential new class of anti-tumor or anti-metastasis agents, one that has shown promising activity against solid tumors. | 11-06-2008 |
20080275107 | TOPICAL FORMULATIONS AND METHODS FOR ELIMINATION AND PROPHYLAXIS OF SUSCEPTIBLE AND TREATMENT RESISTANT STRAINS OF HEAD LICE WITH MULTIPLE MODES OF ACTION - Topical formulations for prophylaxis or elimination of susceptible and treatment resistant head lice wherein the formulation is an aqueous dispersion of an oil phase containing an effective amount of an active ingredient component combining at least one compound that binds to glutamate-gated chloride ion channels and at least one compound that binds to gamma-amino butyric acid (GABA) receptors, dissolved in at least one water-soluble or water-miscible surface active agent with one or more suspending agents and one or more non-ionic surfactants. Also disclosed are methods of using the topical formulations to treat or prevent an infestation of either a susceptible or treatment resistant strain of head lice in a human patient. | 11-06-2008 |
20080275108 | VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF - The present invention provides vacuolar-type (H+)-ATPase-inhibiting compounds, compositions thereof, and methods of using them to treat or prevent a condition treatable by the inhibition of a vacuolar-type (H+)-ATPase. The composition of the present invention comprises a compound of the present invention and a carrier. The method of the present invention includes administering a vacuolar-type (H+)-ATPase inhibiting-effective amount of a compound of the present invention. The compound of the present invention has the formula: | 11-06-2008 |
20080280973 | Laulimalide Analogues as Therapeutic Agents - Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described. | 11-13-2008 |
20080293805 | DRUG DELIVERY SYSTEM AND THE PREPARING METHOD THEREOF - A drug delivery system comprises a liposome and at least one charged nanoparticle. The liposome has at least an internal lipid layer and an external lipid layer, wherein the internal lipid layer forms an interior space for accommodating a drug. The charged nanoparticle is reversibly associated with an exterior surface of the external lipid layer of the liposome. | 11-27-2008 |
20080300298 | Honokiol Derivates For the Treatment of Proliferative Disorders - The present invention provides novel honokiol derivatives, as well as pharmaceutical compositions containing the honokiol derivatives. These compounds and pharmaceutical compositions can be used in the prevention and/or treatment of cancer. In particular, honokiol derivatives, pharmaceutical compositions comprising the derivatives, and methods for their use in the treatment of myeloma are provided. | 12-04-2008 |
20080306138 | STABLE NON-AQUEOUS POUR-ON COMPOSITIONS - The present invention relates to a stable, antiparasitic, non-aqueous pour-on parasiticidal composition which comprises an effective amount of amitraz, optionally a macrocyclic lactone, a stabilizer and a carrier system having no active hydroxyl group. | 12-11-2008 |
20080319049 | Compounds For the Treatment of Metabolic Disorders - Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R | 12-25-2008 |
20090012154 | Antagonists of the transient receptor potential vanilloid 1 and uses thereof - One of the major disabling symptoms of gastroparesis is nausea and vomiting which can be difficult to control with currently available treatments. It is postulated that signaling of gastrointestinal causes of nausea starts with activation of vagal afferent nerves that trigger the central emetic pathway. Most vagal afferent nerves are unmyelinated C-fibers, many of which express the vanilloid receptor TRPV1 and respond to capsaicin. Resiniferatoxin is a very potent capsaicin analogue that has a much more favorable ratio of desensitization to excitation than capsaicin leading to more effective desensitization without irritation. The present invention demonstrates that desensitization of TRPV1 responsive gastric sensory neurons would attenuate nausea and vomiting. | 01-08-2009 |
20090018184 | Polyether Brevetoxin Derivatives as a Treatment for Cystic Fibrosis, Mucociliary Dysfunction, and Pulmonary Diseases - Disclosed are compounds that are derivatives of brevetoxin, or PbTx, pharmaceutical formulations comprising the compounds, and methods of regulating mucus transport in a cell, treating mucociliary dysfunction and diseases related to decreased mucus transport, wherein the compounds are of the Formula (I), and Formula (III): | 01-15-2009 |
20090030068 | Antitumour Compounds - The invention relates to novel antitumor compounds of general formula | 01-29-2009 |
20090042971 | METHOD OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg). | 02-12-2009 |
20090042972 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg). | 02-12-2009 |
20090048332 | Natural Novel Antioxidants - New antioxidants derived from lichen extracts are reported; lecanoric acid, erythrin, sekikaic acid, and lobaric acid were reported as potent natural antioxidants for the treatment of disease and protection of products from the effect of oxidizing components. | 02-19-2009 |
20090048333 | Zearalenone Macrolide Derivatives and Uses of the Same - The present invention provides compounds, pharmaceutical compositions and methods for the treatment of specific cancers. Such compositions may generally comprise a compound of formula (I): | 02-19-2009 |
20090069412 | DEUTERIUM-ENRICHED SUGAMMADEX - The present application describes deuterium-enriched sugammadex, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090069413 | DEUTERIUM-ENRICHED OLOPATADINE - The present application describes deuterium-enriched olopatadine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090082425 | COMPOUNDS FROM MYROTHECIUM SP. FOR INHIBITING THE GROWTH OF CANCER CELLS - The present invention relates to a tumor-inhibiting compound, in particular to verrucarin A and verrucarin J isolated from | 03-26-2009 |
20090082426 | DIMERS OF ARTEMISININ DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The present invention relates to dimers of artemisinin derivatives, to processes for the preparation of such dimers, to methods of treatment comprising administration of such dimers, and to intermediates to such dimers. | 03-26-2009 |
20090099252 | NOVEL LAULIMALIDE ANALOGUES AS THERAPEUTIC AGENTS - Laulimalide analogues useful as microtubule stabilizing agents, and in the treatment of abnormal cell proliferation, are disclosed. Methods of making the compounds, as well as methods of using such compounds in treating abnormal cell proliferation diseases are also described. | 04-16-2009 |
20090163575 | SOLVENT SYSTEMS FOR POUR-ON FORMULATIONS FOR COMBATING PARASITES - This invention relates to pharmaceutical and veterinary formulations providing enhanced solvency and stability for pharmaceutical and veterinary agents for administration to animals, especially ruminants. In addition, the invention relates to pour-on formulations for combating parasites in animals, such as cattle and sheep. In some embodiments, this invention provides glycol-ether-based pour-on formulations comprising a composition comprising a flukicide, such as, for example, clorsulon (4-amino-6-trichloroethenyl-1,3-benzene disulfonamide) and/or a macrolide anthelmintic or antiparasitic agent. In other embodiments, the invention provides pour-on formulations comprising at least one active agent, a glycol ether, and a stability enhancer. This invention also provides for methods for eradicating, controlling, and/or preventing parasite infestation in animals, such as cattle and sheep. | 06-25-2009 |
20090170925 | Methods for prognosing the ability of a zearalenone analog compound to treat cancer - The instant invention provides methods of prognosing the ability of a zearalenone analog compound to treat a cancer in a subject, methods of prognosing the ability of a zearalenone analog compound to inhibit the growth of a cancer in a subject, and methods of prognosing the ability of a zearalenone analog compound to promote the activation of apoptosis of a cancer in a subject. Methods of treating a cancer in a subject are also provided. The invention also pertains to methods of determining whether a cancer in a subject is sensitive to treatment with a zearalenone analog compound. | 07-02-2009 |
20090176866 | Complexes having adjuvant activity - A complex that comprises a narrow molecular weight distribution polymer that includes units derived from an acrylic acid or a salt thereof, and (i) a substance that has pharmacological activity against a pathogenic organism, or (ii) a substance that has pharmacological activity against a cancer, or (iii) one or more agents selected from antigens and immunogens is useful in treating and/or inducing immunity to the pathogenic organism or the cancer, and for inducing immunity to the antigen or immunogen. | 07-09-2009 |
20090176867 | USE OF N-(DIBENZ(B,F)OXEPIN-10-YLMETHYL)-N-METHYL-N-PROP-2-YNYLAMINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT THEREOF FOR THE PROPHYLAXIS AND/OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY - The invention relates to the use of a compound of the formula (I) | 07-09-2009 |
20090176868 | Amidoacetonitrile Derivatives - The invention relates to compounds of the general formula (I) wherein X, Y and W have the significances given in claim | 07-09-2009 |
20090192215 | Cytotoxin Compounds and Methods of Isolation - The present invention concerns groups of compounds derived from tunicates of the | 07-30-2009 |
20090192216 | Methods for the formulation and manufacture of artesunic acid for injection - A method for the manufacture of a sterile intravenous or intramuscular formulation of artesunic acid and the formulation are the subject of this invention. First the artesunic acid powder is sterilized with ethylene oxide and placed into a sterile container. The contained sterilized powder is then dissolved in sterile sodium phosphate buffered solution to produce an injectable intravenous or intramuscular formulation. The sodium phosphate dissolves and dilutes the artesunic acid powder without caking or frothing resulting in an improved drug product. The invention also relates to the formulation and a method of treating a patient with either uncomplicated or severe and complicated malaria. | 07-30-2009 |
20090197938 | Polyphenol Type Compounds, Compositions Containing Same and Use Thereof for Preventing or Treating Diseases Involving Abnormal Cell Proliferation - The invention concerns compounds of formula (I), wherein —X | 08-06-2009 |
20090197939 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS - A method for treating skin, reducing oxidative damage to a skin cell, reducing lipoxygenase (LO) activity in a skin cell, reducing cyclooxygenase (COX) activity in a skin cell, reducing tumor necrosis factor alpha (TNF-α) in a skin cell, or reduction matrix metalloproteinase enzyme activity in a skin cell comprising contacting skin or a skin cell with an aromatic skin-active ingredient. | 08-06-2009 |
20090197940 | CHONDROPSIN-CLASS ANTITUMOR V-ATPase INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - A composition comprising a substantially purified compound of the formula: | 08-06-2009 |
20090203770 | COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING Bcl-2 FAMILY MEMBER PROTEINS - The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding affinity for cytochrome B. Pharmaceutical uses of the agents and compositions include treating apoptosis-associated disease, such as neoplasia and drug resistance, are also disclosed. | 08-13-2009 |
20090203771 | NOVEL INTERMEDIATE FOR HALICHONDRIN B ANALOG SYNTHESIS AND NOVEL DESULFONYLATION REACTION USED FOR THE INTERMEDIATE - The present invention provides a novel method for producing a compound represented by formula (III) shown below, which comprises treating a compound represented by formula (I) shown below with a trivalent chromium compound and at least one kind of metal selected from the group consisting of manganese and zinc in a solvent in the presence of a ligand represented by formula (II) shown below, and the present invention further provides the novel compound represented by formula (I). | 08-13-2009 |
20090209632 | Percutaneously Absorptive Ophthalmic Preparation Comprising Olopatadine - The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine or a salt thereof to the skin surface including the skin surface of an eyelid, thereby casing transfer of a therapeutically effective amount of olopatadine or a salt thereof from the preparation to an anterior ocular segment through the skin of the eyelid rather than a systemic blood flow. The present preparation can exert a pharmacological effect over a prolonged period by a single application, as compared to conventional preparations such as eye drops. | 08-20-2009 |
20090209633 | Treatment of Pain With Resiniferatoxin and Related Analogs - A method of treating inflammatory pain conditions is provided that involves administering an effective amount of a TRPV1 agonist, such as resiniferatoxin, tinyatoxin and related potent agonists and their analogs, to a patient to selectively induce nerve terminal depolarization block and/or nerve terminal death in select TRPV1-containing neurons, to provide the desired pain relief without significant permanent damage to cell bodies of the select TRPV-1 containing neurons. | 08-20-2009 |
20090215884 | METHOD FOR WOUND HEALING - The present invention relates generally to methods and compositions for promoting wound healing in a subject. In particular, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in wound healing and compositions therefor which contain such compounds. | 08-27-2009 |
20090221689 | Macrocyclic Modulators of the Ghrelin Receptor - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders. | 09-03-2009 |
20090233996 | AVERMECTIN/BENZOYL PEROXIDE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea. | 09-17-2009 |
20090247616 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY - The present invention is a method for the treatment of anxiety and related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment of anxiety and related disorders, which includes mono-therapy and alternatively, co-therapy with at least one anxiolytic. | 10-01-2009 |
20090253781 | Therapeutic compositions - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. | 10-08-2009 |
20090264516 | Milbemycin compounds and treatment of dermatological disorders in humans therewith - Compounds of the milbemycin family or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea. | 10-22-2009 |
20090270492 | BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES - Biologically active compounds related to the bryostatin family of compounds, including methods of utilizing the same. | 10-29-2009 |
20090270493 | CYCLIC 1-(ACYLOXY)-ALKYL PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF - The present invention provides cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, methods of making cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. The present invention also provides methods of using cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs and compositions of cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs. | 10-29-2009 |
20090286866 | Double compartment skincare products comprising avermectin/milbemycin compounds - Double compartment skincare products confine a first compartment containing an anhydrous composition including an active ingredient, and a second compartment, wherein the active ingredient is selected from among compounds of the avermectin family and compounds of the milbemycin family, and are useful as medicaments for the treatment and/or prevention of dermatological conditions/afflictions. | 11-19-2009 |
20090286867 | COMPOSITIONS AND METHODS OF ADMINISTERING DOXEPIN TO MUCOSAL TISSUE - Compositions and methods for pain relief involve delivery of doxepin to mucosal tissue. Vehicles for administering doxepin may be formulated for sustained release and/or site-specific application to maximize beneficial pain relief locally while minimizing significant adverse side effects. | 11-19-2009 |
20100010076 | Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs and Methods of Use and Manufacture Thereof - The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to | 01-14-2010 |
20100041745 | Aigialomycin D and Derivatives Thereof and Their Use in Treating Cancer or Malaria or a Microbial Infection - The invention describes a process for making compound (2), comprising the step of cyclising diene (3). Compound (2) may be aigialomycin D or a derivative thereof or may be elaborated to make aigialomycin D or derivative thereof. Furthermore compound (2) or derivative thereof can be used in treating cancer or malaria or a microbial infection. | 02-18-2010 |
20100048686 | Perfume Composition For Temperature Sense Control, Sense Control Article, Sense Control Method, And Perfume Map - It is an object of the present invention to discover that a perfume can change a person's temperature sense and humidity sense, to identify a perfume component that can change temperature sense, and to provide a perfume composition for controlling temperature sense that contains this perfume component, and to a sense control method or sense control article such as an aromatic or a cosmetic that is beneficial for controlling temperature sense, and to a perfume map for selecting a perfume suited to controlling temperature sense. The perfume composition is characterized in that a perfume component that changes the temperature subjectively sensed by a person (temperature sense) is contained, and that the perfume component that changes the temperature sense is a perfume component identified on the basis of a temperature image obtained from test subject assessment. | 02-25-2010 |
20100056615 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS - The present invention refers to the use of at least one tricyclic diterpenes for the manufacture of a nutraceutical or pharmaceutical for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders. | 03-04-2010 |
20100056616 | IEJIMALID ANALOGA AND USES THEREOF - The invention relates to Iejimalides having the following formula (I) in which a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p are simple or double bonds, the continuous lines representing at least one simple bond, the dotted lines representing a possible bond. A double bond can be present but it is not necessary, and provided that a continuous line is also present, or a simple bond can be present if no other line is represented; m=0-20 and n1-n18=1, 2. The bonds can be used as chemotherapeutic agents for treating cancer. | 03-04-2010 |
20100063137 | Cytotoxin Compound And Method of Isolation - The present invention concerns compounds derived from tunicates of the species | 03-11-2010 |
20100069474 | NOVEL COUMARIN DERIVATIVES AS ION CHANNEL OPENERS - The present invention is directed to novel coumarin derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels | 03-18-2010 |
20100087516 | ANTIBACTERIAL MACROLACTIN A THAT BACILLUS POLYFERMENTICUS KJS-2 PRODUCED IN - The present invention relates to uses of Macrolactin A produced by | 04-08-2010 |
20100093842 | Laulimalide Analogs and Uses Thereof - The present invention provides compounds having formula I: | 04-15-2010 |
20100113582 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS - Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases. | 05-06-2010 |
20100137419 | ANTI-CANCER AGENT - Disclosed is a novel anti-cancer agent which is less likely to be excreted from a cancer cells and is suitable for the local treatment against a cancer cell. The anti-cancer agent comprises a rotaxane compound represented by chemical formula (I) as an active ingredient. The rotaxane compound is composed of two moieties; namely, a rod-like moiety having a relatively large molecule attached to each of both ends, and a cyclic moiety (a crown ether) into which the rod-like moiety has been inserted. The cyclic moiety cannot be detached from the rod-like moiety, because the rod-like moiety has a relatively large molecule attached to each of both ends and the relatively large molecules serves as a stopper for the detachment. The bond between the two moieties is not a covalent bond. Therefore, the shape of the molecule can be varied readily, and the uptake of the molecule via a receptor becomes relatively difficult. However, once the molecule is introduced into a cancer cell, the proliferation of the cancer cell can be inhibited. | 06-03-2010 |
20100160424 | RENIN INHIBITORS - Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof. | 06-24-2010 |
20100179214 | DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders | 07-15-2010 |
20100179215 | DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders | 07-15-2010 |
20100184846 | Methods for the formulation and manufacture of artesunic acid for injection - A method for the manufacture of a sterile intravenous or intramuscular formulation of artesunic acid and the formulation are the subject of this invention. First the artesunic acid powder is sterilized with ethylene oxide and placed into a sterile container. The contained sterilized powder is then dissolved in sterile sodium phosphate buffered solution to produce an injectable intravenous or intramuscular formulation. The sodium phosphate dissolves and dilutes the artesunic acid powder without caking or frothing resulting in an improved drug product. The invention also relates to the formulation and a method of treating a patient with either uncomplicated or severe and complicated malaria. | 07-22-2010 |
20100190843 | Tubulin Isotype Screening in Cancer Therapy Using Halichondrin B Analogs - Chemotherapeutic agents that interfere with microtubule assembly or disassembly in the cell are potent inhibitors of cell replication. Examples of such agents include halichondrin B analogs. It has been shown that the susceptibility of certain cancers to analogs of halichondrin B correlates with the expression of particular tubulin isotypes or other microtubule-associated proteins such as MAP-4 and stathmin. Correlations such as these may be used in identifying patients suitable for treatment using a particular chemotherapeutic agent. Such a system avoids treating patients with cytotoxic compounds where there is a minimal or no effect on the cancer. The invention also provides a system of establishing these correlations for different compounds and cancer types. The system will be particularly useful in establishing correlations between anti-microtubule agents and cancers such as lung, breast, and ovarian cancer. Kits and reagents useful in practicing the invention are also provided. | 07-29-2010 |
20100197777 | Synergistic combination of analgesic compounds - The present invention relates to a pharmaceutical composition comprising as active substances:
| 08-05-2010 |
20100216869 | ARTEMISININ DERIVATIVES FOR THE TREATMENT OF MELANOMA - The invention relates to Artemisinin derivatives of general formula (I) | 08-26-2010 |
20100216870 | Novel Genes Encoding a Nystatin Polyketide Synthase and Their Manipulation and Utility - The invention provides a nucleic acid molecule comprising: (a) a nucleotide sequence as shown in SEQ ID No. 35; or (b) a nucleotide sequence which is the complement of SEQ ID No. 35; or (c) a nucleotide sequence which is degenerate with SEQ ID No. 35; or (d) a nucleotide sequence hybridising under conditions of high stringency to SEQ ID No. 35, to the complement of SEQ ID No. 35, or to a hybridisation probe derived from SEQ ID No. 35 or the complement thereof; or (e) a nucleotide sequence having at least 80% sequence identity with SEQ ID No. 35; or (f) a nucleotide sequence having at least 65% sequence identity with SEQ ID No. 35 wherein said sequence preferably encodes or is complementary to a sequence encoding a nystatin PKS enzyme or a part thereof. Also provided are part of such molecules and polypeptides (and parts thereof) encoded by such a nucleic acid molecule, and the use of such molecules and polypeptides in facilitating nystatin biosynthesis and in the synthesis of nystatin derivatives and novel polyketide as macrolide structures. | 08-26-2010 |
20100216871 | USE OF COMPOUNDS HAVING CCR ANTAGONISM - It is intended to provide preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism. | 08-26-2010 |
20100227916 | N-DESMETHYL-DOXEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to desmethyldoxepin, isomers of desmethyldoxepin, and pharmaceutically acceptable salts and prodrugs of desmethyldoxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders. | 09-09-2010 |
20100227917 | EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE - The present invention provides an eye drop comprising: a dibenz[b,e]oxepine derivative or a salt thereof and a polyvalent weak acid, an acidic amino acid or an amide thereof, a basic amino acid or an amide thereof, or the salt thereof, and the like, for the purpose of providing an eye drop or a preparation for topical administration which enables the concentration of a dibenz[b,e]oxepin derivative or a salt thereof to be high; or an eye drop or a preparation for topical administration comprising the dibenz[b,e]oxepine derivative or the salt thereof and having an effective composition for treating allergic disturbance or inflammatory disorder of an eye or for treating allergic disturbance or inflammatory disorder of a nose. | 09-09-2010 |
20100249222 | METHODS OF TREATING SKIN WITH AROMATIC SKIN-ACTIVE INGREDIENTS - A method for treating skin, reducing oxidative damage to a skin cell, reducing lipoxygenase (LO) activity in a skin cell, reducing cyclooxygenase (COX) activity in a skin cell, reducing tumor necrosis factor alpha (TNF-α) in a skin cell, or reduction matrix metalloproteinase enzyme activity in a skin cell comprising contacting skin or a skin cell with an aromatic skin-active ingredient. | 09-30-2010 |
20100292315 | METHOD FOR THE TREATMENT OF FOOD, FEED AND AGRICULTURAL PRODUCTS WITH A POLYENE ANTIFUNGAL COMPOUND - The present invention provides an aqueous antifungal composition comprising a polyene antifungal compound and a thickening agent. The composition can be used in the protection against the development of fungi on food, feed and agricultural products. | 11-18-2010 |
20100324129 | ECTOPARASITICIDAL METHODS AND FORMULATIONS - Provided are novel methods and formulations for topically controlling ectoparasite infestations in animals using spinetoram or a pharmaceutically acceptable salt thereof. | 12-23-2010 |
20110009479 | Stimulating Neuronal Growth Using Brevetoxins - Disclosed are methods of treating neurodegenerative diseases or disorders in a subject in need of such treatment. The methods comprise administering to a subject in need of such treatment a therapeutically effective amount of brevetoxin or brevetoxin derivatives. Included in the diseases and disorders are Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, Multiple sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease) and other Motor Neuron Diseases, Prion Diseases, Frontotemporal Dementia (FTD), and CNS dysfunctions such as schizophrenia, depression, and epilepsy. Also included are neurodegenerations resulting from stroke, heart attack, head and spinal cord trauma, traumatic brain injury, bleeding in the brain and other injuries to the central nervous system (CNS). | 01-13-2011 |
20110015260 | ANTI-MALARIAL PHARMACEUTICAL COMPOSITION - The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions. | 01-20-2011 |
20110021613 | PLANTS EXTRACTS FOR USE IN BRAIN MODULATION - Compounds obtainable from plants, e.g. of the genus | 01-27-2011 |
20110034547 | CHONDROPSIN-CLASS ANTITUMOR V-ATPASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - A composition comprising a substantially purified compound of the formula: | 02-10-2011 |
20110039922 | 18beta-GLYCYRRHETINIC ACID DERIVATIVES AND SYNTHETIC METHOD THEREOF - The present invention provides a chemical compound having the structure being one selected from a group consisting of | 02-17-2011 |
20110082194 | Synergistic Anticoagulant Composition - A composition is provided that, when utilized in combination with warfarin, greatly improves the anticoagulant effects of warfarin in mammalian subjects. The composition is a compound having a naphthohydroquinone ring system substantially similar to the ring system of the reduced form of vitamin K | 04-07-2011 |
20110092582 | New Terpenes And Macrocycles - Novel terpenes and macrocycles are activators of TGR5 and can be used for the prevention and/or treatment of Diabetes Type 2, obesity, neuropathy and/or nephropathy. | 04-21-2011 |
20110166215 | METHODS OF IMPROVING THE PHARMACOKINETICS OF DOXEPIN - Methods of improving the pharmacokinetics of doxepin in a patient. | 07-07-2011 |
20110178166 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg). | 07-21-2011 |
20110190388 | URSOLIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF - Several ursolic acid derivatives and pharmaceutical compositions thereof are provided. The ursolic acid derivatives and the pharmaceutical compositions thereof have at least one of an anticancer and an anti-inflammatory effects. A method for increasing a reactive oxygen species in a cell is also provided. The method comprises a step of providing the cell with a pharmaceutical composition including an ursolic acid derivative. | 08-04-2011 |
20110196028 | PCK ACTIVATION AS A MEANS FOR ENHANCING sAPPa SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS - This invention provides a method for isolating and identifying proteins participating in protein-protein interactions in a complex mixture. The method uses a chemically reactive supporting matrix to isolate proteins that in turn non-covalently bind other proteins. The supporting matrix is isolated, and the non-covalently bound proteins are subsequently released for analysis. Because the proteins are accessible to chemical manipulation at both the binding and release steps, identification of the non-covalently bound proteins yields information on specific classes of interacting proteins, such as calcium-dependent or substrate-dependent protein interactions. This permits selection of a subpopulation of proteins from a complex mixture on the basis of specified interaction criteria. The method has the advantage of screening the entire proteome simultaneously, unlike two-hybrid systems or phage display methods which can only detect proteins binding to a single bait protein at a time. The method is applicable to the study of protein-protein interactions in biopsy and autopsy specimens, to the study of protein-protein interactions in the presence of signaling molecules, pharmacological agents or toxins, and for comparison of diseased and normal tissues or cancerous and untransformed cells. | 08-11-2011 |
20110257254 | Adamantane Derivatives Of Aza-Crown Ethers And Their Use In Treatment Of Tumor - The invention relates to adamantane diaza-crown ether derivatives and the use of mono and diaza-crown ether adamantine derivatives in treatment, especially in tumor treatment. Adamantane aza-crown ethers were obtained by reaction of the corresponding adamantane derived tosylates or adamantane acid chlorides with mono- and diaza-18-crown-6. The prepared compounds showed moderate (monoaza-18-crown-6) to strong (diaza-18-crown-6) antiproliferative and cytotoxic activity on several tumor cell lines, revealing their potential for inhibiting the growth of other tumor cells. | 10-20-2011 |
20110288163 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders. | 11-24-2011 |
20110306658 | Novel compound obtained from gamboge resin, and medical uses of the same - Disclosed herein are seventeen new compounds obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds have activities in inhibiting the growth of tumor/cancer cells. | 12-15-2011 |
20110306659 | OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION - Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine. | 12-15-2011 |
20120010277 | AVERMECTIN COMPOUNDS AND TREATMENT OF DERMATOLOGICAL DISORDERS IN HUMANS THEREWITH - Compounds of the avermectin family or derivatives thereof, notably latidectin, are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea. | 01-12-2012 |
20120010278 | Use of Artemisinin for Treating Tumors Induced by Oncogenic Viruses and for Treating Viral Infections - In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds. | 01-12-2012 |
20120022149 | PHARMACEUTICAL COMPOSITION WITH ENHANCED SOLUBILITY CHARACTERISTICS - There are disclosed pharmaceutical compositions, particularly ophthalmic compositions, that contain relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents. In a preferred embodiment, the composition is a multi-dose topical aqueous ophthalmic composition that contains relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents. | 01-26-2012 |
20120022150 | TREATMENT AND PREVENTION OF BENIGN PIGMENTED MOLES (NAEVI) USING ARTEMISININE AND THE DERIVATIVES THEREOF - A method of treating a benign pigmented mole or a dermatomycosis. The method comprises locally applying to a subject in need thereof artemisinine and/or one or more structurally related compounds. Also disclosed is a plaster which comprises a topical formulation comprising artemisinine and/or one or more structurally related compounds. | 01-26-2012 |
20120059050 | GARCINIA DERIVATIVE, ITS PREPARING METHOD AND MEDICINAL USE - The present invention relates to a field of pharmaceutical chemistry, more specifically, the present invention relates to a garcinia derivative Formula (I), its preparing method, and medicinal use. Wherein the definitions of R | 03-08-2012 |
20120065256 | MILBEMYCIN COMPOUNDS AND TREATMENT OF DERMATOLOGICAL DISORDERS IN HUMANS THEREWITH - Compounds of the milbemycin family or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea. | 03-15-2012 |
20120065257 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE - The present invention is a method for the treatment or prevention of migraine comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment and/or prevention of migraine, which includes mono-therapy and alternatively, co-therapy with at least anti-migraine agent. | 03-15-2012 |
20120071547 | COMPOUNDS FROM SOFT CORAL, METHOD OF PREPARATION AND PHARMACEUTICAL USES THEREOF - The invention relates to compounds from the soft coral and the generation thereof. The invention also relates to the uses of the compounds from the soft coral in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2. | 03-22-2012 |
20120071548 | Therapeutic compositions - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. | 03-22-2012 |
20120071549 | ANTI-INFLAMMATORY COMPOSITION CONTAINING MACROLACTIN A AND A DERIVATIVE THEREOF AS ACTIVE INGREDIENTS - The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novel | 03-22-2012 |
20120088822 | LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS - Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals. | 04-12-2012 |
20120122964 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES - Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc. | 05-17-2012 |
20120157518 | Sublingual Spray Formulation Comprising Dihydroartemesinin - The invention provides pharmaceutical compositions for the treatment of neoplastic diseases, fluke infestations and Lyme disease, comprising compounds capable of providing dihydroartemesinin and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions. | 06-21-2012 |
20120157519 | TELLERIUM-CONTAINING COMPOUNDS FOR TREATING VIRAL INFECTIONS - Tellurium-containing compounds identified for use in a method of treating, or prophylaxis against, a viral infection caused by an influenza virus, uses thereof and pharmaceutical kits and pharmaceutical corn positions comprising the same, are disclosed. The tellurium-containing compounds disclosed herein are suitable for co-administration with an antiviral agent. | 06-21-2012 |
20120190734 | COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION - Compounds from | 07-26-2012 |
20120245222 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg). | 09-27-2012 |
20120245223 | USE OF GYMNODIMINE, ANALOGUES AND DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH TAU AND B-AMYLOID - The present invention refers to the use of a compound with the chemical structure | 09-27-2012 |
20120283321 | USE OF GAMBIEROL FOR TREATING AND/OR PREVENTING NEURODEGENERATIVE DISEASES RELATED TO TAU AND BETA-AMYLOID - The present invention relates to the use of a compound with the following chemical structure: | 11-08-2012 |
20120295967 | HIGH CONCENTRATION OLOPATADINE OPHTHALMIC COMPOSITION - The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis. | 11-22-2012 |
20120316227 | CHRYSOPHAENTIN ANTIMICROBIAL COMPOUNDS THAT INHIBIT FTSZ PROTEIN - Embodiments of antimicrobial chrysophaentin compounds, pharmaceutical compositions including the chrysophaentin compounds, and methods for using the chrysophaentin compounds are disclosed. Some embodiments of the disclosed compounds are isolated from | 12-13-2012 |
20120316228 | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon. | 12-13-2012 |
20120316229 | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon. | 12-13-2012 |
20130018090 | LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS - Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals. | 01-17-2013 |
20130030044 | NEW SERIES OF ARTEMISININ DERIVATIVES AND PROCESS FOR PREPARATION THEREOF - This invention relates to the synthesis of certain novel Baylis-Hillman adducts of artremisinin derived aldehyde 2[10′β-deoxoartemisininyl]-ethanal. The capabilities of introduction of three functional groups into a molecule in one step using Baylis-Hillman reaction encouraged us to synthesize some highly functionalized derivatives of artemisinin. These highly functionalized artemisinin derivatives embodied in this document are found to be active against various cancer cell-lines | 01-31-2013 |
20130041021 | METHODS OF IMPROVING THE PHARMACOKINETICS OF DOXEPIN - Methods of improving the pharmacokinetics of doxepin in a patient. | 02-14-2013 |
20130053434 | IRREVERSIBLE INHIBITORS USEFUL FOR THE TREATMENT OF KINASE-RELATED PATHOLOGIES - The present invention provides new compounds having a kinase inhibitory activity and useful for treating cancer. | 02-28-2013 |
20130072550 | PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS - The present disclosure relates to methods of administering compounds for treating conditions associated with amyloid processing such as Alzheimer's Disease. Methods are disclosed comprising the step of administering a macrocyclic lactone, a benzolactam, a pyrrolidinone or a combination thereof to a subject in need in an amount effective to decrease soluble Aβ-40 or Aβ-42, or to lower total amyloid precursor protein (“APP”). Methods are also disclosed further comprising the step of identifying a subject with increased soluble Aβ-40 or Aβ-42 levels, or elevated APP levels compared to a control population. | 03-21-2013 |
20130096188 | DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders | 04-18-2013 |
20130102658 | DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders | 04-25-2013 |
20130109745 | ANTI-ANGIOGENIC COMPOSITION CONTAINING MACROLACTIN A AND A DERIVATIVE THEREOF AS ACTIVE INGREDIENTS | 05-02-2013 |
20130137759 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASE - The present invention features compositions and methods for treatment of parasitic diseases and cancer. The compositions include | 05-30-2013 |
20130143956 | LONG-ACTING INJECTABLE MOXIDECTIN FORMULATIONS AND NOVEL MOXIDECTIN CRYSTAL FORMS - This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals. | 06-06-2013 |
20130150434 | METHODS OF USING LOW-DOSE DOXEPIN FOR THE IMPROVEMENT OF SLEEP - Methods of treating sleep disorders by administration of low doses of doxepin in individuals seeking sustained efficacy or in need of avoiding weight gain, rebound insomnia, or sedative tolerance resulting from doxepin treatment. | 06-13-2013 |
20130231384 | METHODS OF STIMULATING CELLULAR GROWTH, SYNAPTIC REMODELING AND CONSOLIDATION OF LONG-TERM MEMORY - The present invention provides methods of slowing or reversing the loss of memory and learning comprising the steps of contacting an effective amount of a PKC activator with a protein kinase C (PKC) in a subject identified with memory loss slowing or reversing memory loss. The present invention provides methods of stimulating cellular growth, neuronal growth, dendritic growth, dendritic spine formation, dendritic spine density, and the translocation of ELAV to proximal dendrites, and synaptic remodeling. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to stimulate the synthesis of proteins sufficient to consolidate long-term memory. The present invention also provides methods of contacting a protein kinase C (PKC) activator with a PKC activator in a manner sufficient to downregulate PKC. | 09-05-2013 |
20130245108 | Novel Antischistosomal Agent - An object of the present invention is to provide a novel antischistosomal agent, and more specifically, to provide a novel drug capable of inhibiting a growth of schistosomes in vivo to prevent development of liver dysfunction due to eggs of the schistosomes in the case of infection with the schistosomes. The novel antischistosomal agent includes as an active ingredient a peroxide derivative. Specifically, the novel antischistosomal agent includes as an active ingredient a peroxide derivative represented by the general formula (I): | 09-19-2013 |
20130261174 | PHARMACEUTICAL AND FOOD COMPOSITIONS FOR PREVENTING OR TREATING DIABETES OR OBESITY - The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the | 10-03-2013 |
20130289102 | AMYRIS ALCOHOL AND ITS ESTER FOR TREATING ACNE - The present invention relates to formulations comprising amyris alcohol or an ester of amyris alcohol or combinations thereof to treat acne in humans. These formulations can further comprise a phytoestrogen such as glabridin and miroestrol, an antioxidant such as tetrahydrocurcumin and naturally occurring peroxides such as artemisinin and dihydroartemisinin and combinations thereof for improved effectiveness in treating acne. | 10-31-2013 |
20130296411 | Use of Artemisinin for Treating Tumors Induced by oncogenic Viruses and for Treating Viral Infections - In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds. | 11-07-2013 |
20130296412 | Artemisinin-Like Derivatives with Cytotoxic and Anti-Angiogenic Properties - The present invention relates to novel artemisinin-like derivates, and especially dihydroartemisinin derivates and pharmaceutical compositions comprising the present compounds. The present invention further relates to the use of the present compounds for the treatment of cancer, especially by oral administration. Especially, the present invention relates to dihydroartemisinin compounds (DHA) substituted by, through an ester linkage by a linear or branched C | 11-07-2013 |
20130296413 | N-DESMETHYL-DOXEPIN AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS - Desmethyldoxepin, isomers of desmethyldoxepin, and pharmaceutically acceptable salts and prodrugs of desmethyldoxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders. | 11-07-2013 |
20130303600 | ANTI-ANGIOGENIC COMPOSITION CONTAINING MACROLACTIN A AND A DERIVATIVE THEREOF AS ACTIVE INGREDIENTS - The present invention relates to an anti-angiogenic composition containing macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A, and 7-O-succinyl macrolactin A as active ingredients. The macrolactin compounds according to the present invention strongly suppress angiogenesis in in vivo experiments and can be used as a pharmaceutical composition for preventing or treating diseases caused by angiogenesis. | 11-14-2013 |
20130317094 | USE OF ELLAGITANNINS AS INHIBITORS OF BACTERIAL QUORUM SENSING - Described herein are materials and methods for the inhibition of bacterial QS. Methods of treating bacterial infections by administration of one or more ellagitannins in amount effective to inhibit bacterial QS is also provided. | 11-28-2013 |
20130317095 | Use of Artemisine Derivatives and Pharmaceutical Salts Thereof - The invention demonstrates the application of an artemisinin derivative and its pharmaceutical salt. The artemisinin derivatives diarteether amine and its pharmaceutical salt inhibit the proliferation of leukemic cells, block the cell cycle of leukemic cells and induce the apoptosis of leukemic cells. Artemisinin derivatives of the present invention and its pharmaceutical salt can be used for the preparation of anti-leukemia medicines, especially for treatment of acute leukemia and, what's more, for the treatment of acute myeloid leukemia. | 11-28-2013 |
20130324595 | C-GLUCOSIDIC ELLAGITANNIN COMPOUNDS FOR USE FOR ALTERING THE SUPRAMOLECULAR ARRANGEMENT OF ACTIN AND FOR THE TREATMENT OF OSTEOPOROSIS, CANCER, BACTERIAL INFECTION AND VIRAL INFECTION - The present invention concerns a C-glucosidic ellagitannin compound or a metabolite thereof for use for altering the supramolecular arrangement of actin in an individual suffering from osteoporosis, cancer, bacterial infection, or viral infection. It also pertains to pharmaceutical compositions comprising a C-glucosidic ellagitannin compound and/or metabolites thereof and one or more physiologically acceptable carriers. It finally concerns a C-glucosidic ellagitannin compound or a metabolite thereof, optionally detectably labeled, for in vitro use as a tool for studying cellular mechanisms involving actin, or for detecting F-actin in a cell. | 12-05-2013 |
20130331444 | TREATMENT OF COGNITIVE DISORDERS ASSOCIATED WITH ABNORMAL DENDRITIC SPINES USING PKC ACTIVATORS - The present disclosure provides methods of treating a cognitive disorder associated with abnormal dendritic spines, such as Fragile X Syndrome, Fragile X Associated Tremor/Ataxia Syndrome, autism, or mental retardation, using PKC activators. | 12-12-2013 |
20140005259 | MICROBICIDAL AND ANTIPARASITIC COMPOSITIONS | 01-02-2014 |
20140011867 | EFFECT OF BORRELIDIN FOR CONTROLLING SOYBEAN PHYTOPHTHORA ROOT ROT - The present invention discloses use of borrelidin for preventing and controlling | 01-09-2014 |
20140024704 | PROCESS FOR THE PREPARATION OF OLOPATADINE - A process for the preparation of olopatadine hydrochloride starting from an advanced intermediate. | 01-23-2014 |
20140024705 | MIGRASTATINS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 01-23-2014 |
20140051750 | LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS - Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals. | 02-20-2014 |
20140088182 | INFLAMMATORY EYE DISEASE - The present invention provides methods, kits and compositions for treating uveitis in a subject using Hsp90 inhibitors. | 03-27-2014 |
20140100268 | OLIGOMER-TRICYCLIC CONJUGATES - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer. | 04-10-2014 |
20140142169 | SN-2-MONOACYLGLYCEROLS AND LIPID MALABSORPTION - The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties. | 05-22-2014 |
20140163095 | USE OF ERIBULIN IN THE TREATMENT OF BREAST CANCER - The invention provides methods of treating breast cancer in subjects having locally advanced or metastatic breast cancer. | 06-12-2014 |
20140179772 | Anti-Malarial Pharmaceutical Composition - The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions. | 06-26-2014 |
20140187618 | COMPOSITIONS, METHODS AND KITS USING FOR INDUCING OR ENHANCING NEUROGENESIS IN CELLS AND TISSUE - Compositions, methods, and kits including extracts containing physalins and pure physalins are provided for inducing neurogenesis in cells and tissues. The extracts for example are obtained from natural sources such as a plant, for example | 07-03-2014 |
20140187619 | TREATMENTS FOR DIABETES MELLITUS AND OBESITY - Methods of treatment in subjects suffering from diabetes mellitus or obesity are provided. The methods comprise the step of administering an active agent directly to the small intestine in the subject. In particular, the active agent may be administered directly to the duodenum in the subject. The active agents useful in the treatments described herein include analgesic agents and, in particular, antinociceptive agents such as capsaicin, resiniferatoxin, and their analogues. | 07-03-2014 |
20140194495 | CYTOTOXIN COMPOUNDS AND METHODS OF ISOLATION - The present invention concerns groups of compounds derived from tunicates of the | 07-10-2014 |
20140194496 | METHODS AND COMPOSITIONS FOR INHIBITING INTEGRINS USING TELLURIUM-CONTAINING COMPOUNDS - Methods and compositions for inhibiting integrin and treating integrin-related conditions, utilizing tellurium-containing compounds, are disclosed. The tellurium-containing compounds comprise at least one tellurium dioxo moiety and may have any one of Formulae I to IV as defined in the specification. Further disclosed are methods and compositions for treating a neoplastic condition characterized by a resistance to an anti-neoplastic agent and by a high level of expression of an integrin by neoplastic cells. | 07-10-2014 |
20140206760 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA - The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoaguability or fibrotic changes. | 07-24-2014 |
20140213642 | NOVEL C-ARYL ANSA SGLT2 INHIBITORS - Disclosed is a novel C-aryl ansa compound having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. Also provided are a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound. | 07-31-2014 |
20140221468 | Compounds that Modulate Store Operated Calcium Channels - Store operated calcium channel modulating compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which modulation of store operated calcium channels is desired. | 08-07-2014 |
20140243402 | Artemisinins in the Clinical and Veterinary Management of Kinetoplastid Infextions - The invention relates to the treatment of kintoplastid infections by administering a pharmaceutical composition containing an extract from the plant | 08-28-2014 |
20140243403 | TREATING COLORECTAL, PANCREATIC, AND LUNG CANCER - The invention relates to methods of determining an appropriate chemotherapy for a subject based on expression levels of a TAK1 biomarker, such as one or more TAK1 biomarkers listed in Table 1, or any subset or combination thereof, e.g., a set of biomarkers consisting of or comprising GGH, BMP7, BAMBI, MBOAT2, HSPA12A, FYN, NAV2, RGL1, SYK and RUNX1 genes, optionally with one or both of INHBB and/or BMPR1A. In some embodiments, the biomarkers include one, two, three, or all of BMP7, BAMBI, BMPR1A, and INHBB. Kits useful for the methods are also provided. | 08-28-2014 |
20140296328 | HIGH CONCENTRATION OLOPATADINE OPHTHALMIC COMPOSITION - The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis. | 10-02-2014 |
20140315990 | PKC ACTIVATORS AND COMBINATIONS THEREOF - The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof. | 10-23-2014 |
20140323559 | LONG-ACTING INJECTABLE MOXIDECTIN FORMULATIONS AND NOVEL MOXIDECTIN CRYSTAL FORMS - This invention provides for novel antiparasitic and pesticidal forms of moxidectin, including a long-acting polymeric implant. The resulting compounds may be used in veterinary compositions which are used in treating, controlling and preventing of endo- and ectoparasite infections in animals. | 10-30-2014 |
20140329893 | THERAPEUTIC COMPOSITIONS - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. | 11-06-2014 |
20140329894 | COMBINATION THERAPY AND USES THEREOF FOR TREATMENT AND PREVENTION OF PARASITIC INFECTION AND DISEASE - The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., | 11-06-2014 |
20150038565 | LONG ACTING COMPOSITIONS - The present invention relates to a long-acting composition for the treatment of an animal in need thereof wherein the composition includes a therapeutically effective amount of a bioactive agent, characterised in that the composition includes a non-aqueous carrier and a solvent system comprising castor oil and at least one cyclic amide. | 02-05-2015 |
20150038566 | REGULATION OF CHOLESTEROL HOMEOSTASIS - The invention provides novel compounds of Formulas (I)-(IV), as described herein. Also provided are compositions of these compounds, method of making the compounds, and methods of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal lipid storage disorders such as Niemann-Pick Disease type C. | 02-05-2015 |
20150065565 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES - Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors). | 03-05-2015 |
20150073042 | Cyclic Peptidomimetic Compounds as Immunomodulators - The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them. | 03-12-2015 |
20150094363 | TRANSPLANTATION THERAPIES - Embodiments of the present invention are directed to methods and dosage forms for treating inflammation and rejection in transplantation injuries with Bryostatin-1, Bryostatin-1 analogs and pharmaceutically acceptable salts thereof. | 04-02-2015 |
20150119455 | FORMULATION - Stable formulations of Olopatadine, methods of making such formulations and methods of treatment using such formulations are provided. | 04-30-2015 |
20150133535 | ANTI-CANCER POLYKETIDE COMPOUNDS - Provided herein, inter alia, are anticancer polyketides. The uses of the polyketides described herein include treatment of cancer, for example, through regulation of the spliceosome and detection of spliceosome inhibition. | 05-14-2015 |
20150291616 | BRYOID COMPOSITIONS, METHODS OF MAKING AND USE THEREOF - Embodiments of the present invention feature novel Bryoid compositions, methods of making and methods of treating disease | 10-15-2015 |
20150297559 | METHODS AND COMPOSITIONS FOR TREATMENT OF LIPID STORAGE DISORDERS - Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids. | 10-22-2015 |
20150299217 | ARTEMISININ DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIMALARIAL AGENTS - Derivatives of the antimalarial agent artemisinin, compositions comprising the derivatives, methods for preparing the derivatives, and their uses in pharmaceutical compositions intended for the treatment of parasitic infections are provided. Methods are provided for the production of artemisinin derivatives via functionalization of positions C7 and C6a, and optionally, in conjunction with modifications at positions C10 and C9, via chemoenzymatic methods. Recombinant cytochrome P450 polypeptides are also provided for use in the methods. The artemisinin derivatives can be used for the treatment of malaria and other parasitic infections, alone or in combination with other antiparasitic drugs. | 10-22-2015 |
20150306065 | A Combination of Adrenaline with an Antidepressant for Use in the Treatment of Shocks - The present invention concerns a novel combination of adrenalin with an antidepressant and its use as a pharmaceutical composition for the treatment of shocks. The pharmaceutical composition is to be administered by injection. | 10-29-2015 |
20150320717 | Methods Of Using Low-Dose Doxepin For The Improvement Of Sleep - Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg). | 11-12-2015 |
20150336981 | MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS - This invention relates to polyphenolic compounds, in particular ethoxylated polyphenolic compounds and the use of such compounds in disease prevention, disease treatment, and life extension in humans and animals. The invention also relates to methods of preparing ethoxylated polyphenolic compounds, and preparation of compositions comprising the compounds, including dietary supplements and foods. The inventors describe how modified C-glycosidic ellagitannins are safe, palatable and effective at medium and high doses, and produce broad and profound health outcomes in mammals. | 11-26-2015 |
20150344493 | ARTEMISININ COMPOUNDS AND SYNTHESIS AND USE THEREOF - The present disclosure describes artemisinin compounds. The compounds can be synthesized using an Ugi synthesis reaction and can be used in the treatment of cancers, parasitic infections and yeast infections. | 12-03-2015 |
20150366837 | SELAMECTIN FOR TREATMENT OF SEA LICE INFESTATIONS - The invention describes a method for treating a parasitic infection or infestation, particularly sea lice, in a fish by administering an effective amount of selamectin. | 12-24-2015 |
20160022629 | Sublingual Spray Formulation Comprising Dihydroartemesinin - The invention provides pharmaceutical compositions for the treatment of neoplastic diseases, fluke infestations and Lyme disease, comprising compounds capable of providing dihydroartemesinin and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions. | 01-28-2016 |
20160022750 | POMEGRANATE FRUIT POLYPHENOL COMPOSITION AND METHODS OF USE AND MANUFACTURE THEREOF - A pharmaceutical composition with an active pharmaceutical ingredient including a pomegranate fruit polyphenol extract. The pomegranate fruit polyphenol extract includes at least about 3% combined punicalagin A and punicalagin B by weight, less than about 5% ellagic acid and their derivatives by weight, and less than about 1% anthocyanins by weight. | 01-28-2016 |
20160024033 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA - The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes. | 01-28-2016 |
20160030383 | LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS - Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe tor elderly individuals. | 02-04-2016 |
20160051509 | METHODS FOR ALZHEIMER'S DISEASE TREATMENT AND COGNITIVE ENHANCEMENT - The present invention relates to compositions and methods to modulate α-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s). | 02-25-2016 |
20160137663 | NOVEL SESQUITERPENOID STAT3 INHIBITORS - The present disclosure provides a method of purifying pharmaceutical compositions consisting essentially of STAT3 inhibitors from a mixture of compounds, pharmaceutical compositions comprising STAT3 inhibitors used to inhibit STAT3 in tumor cells, and certain pharmaceutically acceptable salts thereof, and methods of use. | 05-19-2016 |
20160166536 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | 06-16-2016 |
20160176895 | METHODS USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS | 06-23-2016 |
20160193126 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | 07-07-2016 |
20160250339 | Pegylated Artesunate Derivative, Pharmaceutical Composition and Use Thereof | 09-01-2016 |
20190142737 | SUBLINGUAL SPRAY FORMULATION COMPRISING DIHYDROARTEMESININ | 05-16-2019 |